Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Busulfan"" wg kryterium: Temat


Tytuł :
Does the order of busulfan and cyclophosphamide affect allogeneic stem cell transplantation related liver toxicity?
Autorzy :
Seydoux C; Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland.
Passweg JR; Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland.
Medinger M; Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2021 May; Vol. 100 (5), pp. 1349-1350. Date of Electronic Publication: 2021 Mar 10.
Typ publikacji :
Letter; Comment
MeSH Terms :
Busulfan*
Hematopoietic Stem Cell Transplantation*
Cyclophosphamide ; Liver
Opinia redakcyjna
Tytuł :
Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis.
Autorzy :
Modi D; Department of Oncology, Karmanos Cancer Institute/Wayne State University, 4100 John R, HW04H0, Detroit, MI, 48201, USA. .
Singh V; Department of Oncology, Karmanos Cancer Institute/Wayne State University, 4100 John R, HW04H0, Detroit, MI, 48201, USA.
Kim S; Biostatistics Core, Karmanos Cancer Institute, Department of Oncology, Wayne State University, Detroit, MI, 48201, USA.
Ayash L; Department of Oncology, Karmanos Cancer Institute/Wayne State University, 4100 John R, HW04H0, Detroit, MI, 48201, USA.
Deol A; Department of Oncology, Karmanos Cancer Institute/Wayne State University, 4100 John R, HW04H0, Detroit, MI, 48201, USA.
Ratanatharathorn V; Department of Oncology, Karmanos Cancer Institute/Wayne State University, 4100 John R, HW04H0, Detroit, MI, 48201, USA.
Uberti JP; Department of Oncology, Karmanos Cancer Institute/Wayne State University, 4100 John R, HW04H0, Detroit, MI, 48201, USA.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2021 Apr; Vol. 100 (4), pp. 969-978. Date of Electronic Publication: 2021 Feb 16.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Peripheral Blood Stem Cell Transplantation*
Antilymphocyte Serum/*therapeutic use
Busulfan/*therapeutic use
Graft vs Host Disease/*prevention & control
Immunosuppressive Agents/*therapeutic use
Leukemia, Myeloid, Acute/*therapy
Myeloablative Agonists/*therapeutic use
Transplantation Conditioning/*methods
Vidarabine/*analogs & derivatives
Aged ; Allografts ; Busulfan/adverse effects ; Female ; Graft vs Host Disease/etiology ; Humans ; Infections/epidemiology ; Lymphocyte Depletion ; Male ; Middle Aged ; Mycophenolic Acid/therapeutic use ; Myeloablative Agonists/adverse effects ; Progression-Free Survival ; Retrospective Studies ; T-Lymphocytes ; Tacrolimus/therapeutic use ; Treatment Outcome ; Unrelated Donors ; Vidarabine/adverse effects ; Vidarabine/therapeutic use ; Whole-Body Irradiation
Czasopismo naukowe
Tytuł :
Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial.
Autorzy :
Seydoux C; Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland.
Medinger M; Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland. .
Gerull S; Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland.
Halter J; Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland.
Heim D; Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland.
Chalandon Y; Division of Hematology, Bone Marrow Transplant Unit, University Hospital of Geneva and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Levrat SM; Division of Hematology, Bone Marrow Transplant Unit, University Hospital of Geneva and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Schanz U; Department of Medical Oncology and Hematology, Stem-/Immune- cell-transplant Unit, University Hospital of Zurich, Zurich, Switzerland.
Nair G; Department of Medical Oncology and Hematology, Stem-/Immune- cell-transplant Unit, University Hospital of Zurich, Zurich, Switzerland.
Ansari M; Department Women, Children and Adolescent, Unit of Oncology and Hematology Pediatric, University Hospital of Geneva, Geneva, Switzerland.; Cansearch Research Laboratory, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Simon P; Clinical Trials Unit, Department of Clinical Research, Basel University, Basel, Switzerland.
Passweg JR; Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland. .
Cantoni N; Division of Oncology, Hematology and Transfusion Medicine, Kantonsspital Aarau, Aarau, Switzerland.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2021 Jan; Vol. 100 (1), pp. 209-216. Date of Electronic Publication: 2020 Oct 23.
Typ publikacji :
Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Busulfan/*administration & dosage
Cyclophosphamide/*administration & dosage
Hematologic Neoplasms/*therapy
Hematopoietic Stem Cell Transplantation/*methods
Immunosuppressive Agents/*administration & dosage
Transplantation Conditioning/*methods
Adult ; Aged ; Busulfan/adverse effects ; Chemical and Drug Induced Liver Injury/diagnosis ; Chemical and Drug Induced Liver Injury/mortality ; Cyclophosphamide/adverse effects ; Drug Therapy, Combination ; Female ; Hematologic Neoplasms/drug therapy ; Hematologic Neoplasms/mortality ; Hematopoietic Stem Cell Transplantation/mortality ; Humans ; Immunosuppressive Agents/adverse effects ; Male ; Middle Aged ; Prospective Studies ; Transplantation Conditioning/mortality ; Transplantation, Homologous/methods ; Transplantation, Homologous/mortality ; Young Adult
Czasopismo naukowe
Tytuł :
Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia.
Autorzy :
Shargian-Alon L; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, 49100, Petah-Tikva, Israel. .; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. .
Wolach O; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, 49100, Petah-Tikva, Israel.; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Rozovski U; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, 49100, Petah-Tikva, Israel.; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Yahav D; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.; Infectious Disease Unit, Rabin Medical Center, Petah-Tikva, Israel.
Sela-Navon M; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, 49100, Petah-Tikva, Israel.
Rubinstein M; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, 49100, Petah-Tikva, Israel.
Oniashvilli N; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.; The Raphael Recanati Genetic Institute, Rabin Medical Center, Petah-Tikva, Israel.
Pasvolsky O; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, 49100, Petah-Tikva, Israel.; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Raanani P; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, 49100, Petah-Tikva, Israel.; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Yeshurun M; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, 49100, Petah-Tikva, Israel.; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Dec; Vol. 99 (12), pp. 2939-2945. Date of Electronic Publication: 2020 Sep 06.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents, Alkylating/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Busulfan/*analogs & derivatives
Leukemia, Myeloid, Acute/*diagnosis
Leukemia, Myeloid, Acute/*therapy
Transplantation Conditioning/*methods
Vidarabine/*analogs & derivatives
Adult ; Aged ; Busulfan/administration & dosage ; Cohort Studies ; Cytarabine/administration & dosage ; Disease-Free Survival ; Female ; Granulocyte Colony-Stimulating Factor/administration & dosage ; Humans ; Idarubicin/administration & dosage ; Leukemia, Myeloid, Acute/mortality ; Male ; Middle Aged ; Retrospective Studies ; Treatment Outcome ; Vidarabine/administration & dosage ; Young Adult
SCR Protocol :
Ida-FLAG protocol
Czasopismo naukowe
Tytuł :
Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas.
Autorzy :
Jo JC; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
Kim JS; Department of Internal Medicine, Severance Hospital, Yeonsei University College of Medicine, Seoul, Korea.
Lee JH; Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Lee JH; Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Im SN; Department of Hematology and Oncology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.
Lee SM; Department of Hematology and Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
Yoon SS; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. .
Kim IH; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Bae SH; Department of Hematology and Oncology, Daegu Catholic University Hospital, Daegu Catholic University School of Medicine, Daegu, Korea.
Lee YJ; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
Choi Y; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
Lee WS; Department of Hematology and Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2021 Jan; Vol. 100 (1), pp. 189-196. Date of Electronic Publication: 2020 Nov 17.
Typ publikacji :
Clinical Trial; Journal Article; Multicenter Study; Observational Study
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Busulfan/*administration & dosage
Cytarabine/*administration & dosage
Etoposide/*administration & dosage
Hematopoietic Stem Cell Transplantation/*methods
Lymphoma, T-Cell, Peripheral/*drug therapy
Melphalan/*administration & dosage
Adult ; Aged ; Antineoplastic Agents, Alkylating/administration & dosage ; Antineoplastic Agents, Phytogenic/administration & dosage ; Dose-Response Relationship, Drug ; Female ; Humans ; Lymphoma, T-Cell, Peripheral/diagnosis ; Lymphoma, T-Cell, Peripheral/epidemiology ; Male ; Middle Aged ; Prospective Studies ; Republic of Korea/epidemiology ; Transplantation Conditioning/methods ; Transplantation, Autologous/methods ; Young Adult
Czasopismo naukowe
Tytuł :
Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma.
Autorzy :
Blanes M; Hematology Service, University Hospital General de Elda, Alicante, Spain.
Lorenzo JI; Hematology Service, University Hospital La Fe, Valencia, Spain.
Ribas P; Hematology Service, University Hospital Doctor Peset, Valencia, Spain.
Jiménez A; Hematology Service, University Hospital 12 de Octubre, Madrid, Spain.
González JD; Hematology Service, University Hospital Insular de Canarias, Las Palmas, Spain.
Cejalvo MJ; Hematology Service, University Hospital Doctor Peset, Valencia, Spain.
Solano C; Hematology Service, University Hospital Clínico, Valencia, Spain.
Alegre A; Hematology Service, University Hospital La Princesa, Madrid, Spain.
de la Rubia J; Hematology Service, University Hospital Doctor Peset, Valencia, Spain. .; Internal Medicine, School of Medicine and Dentistry, Catholic University of Valencia, Valencia, Spain. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2019 Aug; Vol. 98 (8), pp. 2013-2015. Date of Electronic Publication: 2019 Mar 16.
Typ publikacji :
Letter
MeSH Terms :
Busulfan/*therapeutic use
Melphalan/*therapeutic use
Multiple Myeloma/*therapy
Transplantation Conditioning/*methods
Busulfan/administration & dosage ; Drug Evaluation ; Follow-Up Studies ; Hematopoietic Stem Cell Transplantation ; Humans ; Melphalan/administration & dosage ; Progression-Free Survival ; Transplantation, Autologous ; Treatment Outcome
Opinia redakcyjna
Tytuł :
The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients.
Autorzy :
Willcox A; Department of Clinical Haematology, Austin Hospital, Melbourne, Australia. .; Australian Centre for Blood Diseases, Monash University, Melbourne, Australia. .
Wong E; Department of Clinical Haematology and Bone Marrow Transplant, The Royal Melbourne Hospital, Melbourne, Australia.
Nath C; The Children's Hospital at Westmead, Sydney, Australia.
Janson B; Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Harrison SJ; Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Hoyt R; Department of Clinical Haematology, Austin Hospital, Melbourne, Australia.
Bajel A; Department of Clinical Haematology and Bone Marrow Transplant, The Royal Melbourne Hospital, Melbourne, Australia.
Shaw P; The Children's Hospital at Westmead, Sydney, Australia.
Ritchie D; Department of Clinical Haematology and Bone Marrow Transplant, The Royal Melbourne Hospital, Melbourne, Australia.
Grigg A; Department of Clinical Haematology, Austin Hospital, Melbourne, Australia.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2018 Dec; Vol. 97 (12), pp. 2509-2518. Date of Electronic Publication: 2018 Jul 26.
Typ publikacji :
Clinical Trial; Journal Article; Multicenter Study
MeSH Terms :
Body Mass Index*
Busulfan*/administration & dosage
Busulfan*/pharmacokinetics
Hematopoietic Stem Cell Transplantation*
Melphalan*/administration & dosage
Melphalan*/pharmacokinetics
Transplantation Conditioning*
Adult ; Aged ; Autografts ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies.
Autorzy :
Khalil MMI; Allogeneic Blood and Marrow Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, 610 University Ave, Toronto, ON, M5G 2M9, Canada.
Messner HA; Allogeneic Blood and Marrow Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, 610 University Ave, Toronto, ON, M5G 2M9, Canada.
Lipton JH; Allogeneic Blood and Marrow Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, 610 University Ave, Toronto, ON, M5G 2M9, Canada.
Kim DD; Allogeneic Blood and Marrow Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, 610 University Ave, Toronto, ON, M5G 2M9, Canada.
Viswabandya A; Allogeneic Blood and Marrow Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, 610 University Ave, Toronto, ON, M5G 2M9, Canada.
Thyagu S; Allogeneic Blood and Marrow Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, 610 University Ave, Toronto, ON, M5G 2M9, Canada.
Deotare U; Allogeneic Blood and Marrow Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, 610 University Ave, Toronto, ON, M5G 2M9, Canada.
Michelis FV; Allogeneic Blood and Marrow Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, 610 University Ave, Toronto, ON, M5G 2M9, Canada. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2018 Oct; Vol. 97 (10), pp. 1975-1985. Date of Electronic Publication: 2018 Jun 11.
Typ publikacji :
Evaluation Study; Journal Article
MeSH Terms :
Peripheral Blood Stem Cell Transplantation*
Whole-Body Irradiation*
Busulfan/*therapeutic use
Leukemia, Myeloid/*therapy
Myelodysplastic Syndromes/*therapy
Transplantation Conditioning/*methods
Vidarabine/*analogs & derivatives
Aged ; Aged, 80 and over ; Allografts ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Busulfan/administration & dosage ; Combined Modality Therapy ; Female ; Follow-Up Studies ; Graft vs Host Disease/etiology ; Humans ; Kaplan-Meier Estimate ; Leukemia, Myeloid/drug therapy ; Male ; Middle Aged ; Myelodysplastic Syndromes/drug therapy ; Ontario ; Retrospective Studies ; Vidarabine/administration & dosage ; Vidarabine/therapeutic use
Czasopismo naukowe
Tytuł :
Phase II study of safety and efficacy of BEB (bendamustine, etoposide, and busulfan) conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphoma.
Autorzy :
Kim DY; Division of Hematology-Oncology, Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, South Korea.
Chung JS; Division of Hematology-Oncology, Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, South Korea.
Jo JC; Division of Hematology-Oncology, Department of Internal Medicine, Ulsan University Hospital, Ulsan, South Korea.
Cho SH; Division of Hematology-Oncology, Departments of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, South Korea.
Shin HJ; Division of Hematology-Oncology, Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, South Korea. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Apr; Vol. 99 (4), pp. 819-828. Date of Electronic Publication: 2020 Feb 05.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Lymphoma, Non-Hodgkin/*drug therapy
Transplantation Conditioning/*methods
Adult ; Antifungal Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bendamustine Hydrochloride/administration & dosage ; Bendamustine Hydrochloride/adverse effects ; Busulfan/administration & dosage ; Busulfan/adverse effects ; Combined Modality Therapy ; Etoposide/administration & dosage ; Etoposide/adverse effects ; Febrile Neutropenia/chemically induced ; Female ; Follow-Up Studies ; Granulocyte Colony-Stimulating Factor/therapeutic use ; Humans ; Kaplan-Meier Estimate ; Lymphoma, Non-Hodgkin/diagnostic imaging ; Lymphoma, Non-Hodgkin/therapy ; Male ; Middle Aged ; Positron Emission Tomography Computed Tomography ; Premedication ; Progression-Free Survival ; Prospective Studies ; Remission Induction ; Transplantation Conditioning/adverse effects ; Transplantation, Autologous ; Young Adult
Czasopismo naukowe
Tytuł :
High leukemia-free survival after TBI-based conditioning and mycophenolate mofetil-containing immunosuppression in patients allografted for chronic myelomonocytic leukemia: a single-center experience.
Autorzy :
Radujkovic A; Department of Internal Medicine V, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. .
Hegenbart U; Department of Internal Medicine V, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Müller-Tidow C; Department of Internal Medicine V, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Herfarth K; Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Dreger P; Department of Internal Medicine V, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Luft T; Department of Internal Medicine V, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Apr; Vol. 99 (4), pp. 855-866. Date of Electronic Publication: 2020 Feb 08.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Whole-Body Irradiation*
Immunosuppressive Agents/*therapeutic use
Leukemia, Myelomonocytic, Chronic/*therapy
Mycophenolic Acid/*therapeutic use
Myeloablative Agonists/*therapeutic use
Transplantation Conditioning/*methods
Adult ; Aged ; Antilymphocyte Serum/therapeutic use ; Busulfan/analogs & derivatives ; Busulfan/therapeutic use ; Calcineurin Inhibitors/therapeutic use ; Disease-Free Survival ; Female ; Humans ; Kaplan-Meier Estimate ; Leukemia, Myeloid, Acute/etiology ; Leukemia, Myeloid, Acute/therapy ; Male ; Melphalan/therapeutic use ; Methotrexate/therapeutic use ; Middle Aged ; Neoplasms, Second Primary/etiology ; Neoplasms, Second Primary/therapy ; Proportional Hazards Models ; Retrospective Studies ; T-Lymphocytes/immunology ; Transplantation, Homologous ; Vidarabine/analogs & derivatives ; Vidarabine/therapeutic use
Czasopismo naukowe
Tytuł :
When an HLA identical donor is not available in adults with hematological neoplasms: single-center comparison of single-unit cord blood transplantation and haploidentical-related PBSC transplantation with PTCy using a standardized conditioning platform (thiotepa-busulfan-fludarabine).
Autorzy :
Esquirol A; Hematology Department, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau and Jose Carreras Leukemia Research Institutes, Universitat Autonoma of Barcelona, Mas Casanovas, 90, 08041, Barcelona, Spain. .
Querol S; Banc de Sang i de teixits de Catalunya, Barcelona, Spain.
Garcia-Cadenas I; Hematology Department, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau and Jose Carreras Leukemia Research Institutes, Universitat Autonoma of Barcelona, Mas Casanovas, 90, 08041, Barcelona, Spain.
Novelli S; Hematology Department, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau and Jose Carreras Leukemia Research Institutes, Universitat Autonoma of Barcelona, Mas Casanovas, 90, 08041, Barcelona, Spain.
Garrido A; Hematology Department, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau and Jose Carreras Leukemia Research Institutes, Universitat Autonoma of Barcelona, Mas Casanovas, 90, 08041, Barcelona, Spain.
Saavedra S; Hematology Department, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau and Jose Carreras Leukemia Research Institutes, Universitat Autonoma of Barcelona, Mas Casanovas, 90, 08041, Barcelona, Spain.
Moreno C; Hematology Department, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau and Jose Carreras Leukemia Research Institutes, Universitat Autonoma of Barcelona, Mas Casanovas, 90, 08041, Barcelona, Spain.
Granell M; Hematology Department, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau and Jose Carreras Leukemia Research Institutes, Universitat Autonoma of Barcelona, Mas Casanovas, 90, 08041, Barcelona, Spain.
Caballero A; Hematology Department, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau and Jose Carreras Leukemia Research Institutes, Universitat Autonoma of Barcelona, Mas Casanovas, 90, 08041, Barcelona, Spain.
Brunet S; Hematology Department, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau and Jose Carreras Leukemia Research Institutes, Universitat Autonoma of Barcelona, Mas Casanovas, 90, 08041, Barcelona, Spain.
Briones J; Hematology Department, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau and Jose Carreras Leukemia Research Institutes, Universitat Autonoma of Barcelona, Mas Casanovas, 90, 08041, Barcelona, Spain.
Martino R; Hematology Department, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau and Jose Carreras Leukemia Research Institutes, Universitat Autonoma of Barcelona, Mas Casanovas, 90, 08041, Barcelona, Spain.
Sierra J; Hematology Department, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau and Jose Carreras Leukemia Research Institutes, Universitat Autonoma of Barcelona, Mas Casanovas, 90, 08041, Barcelona, Spain.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Jan; Vol. 99 (1), pp. 157-165. Date of Electronic Publication: 2019 Dec 17.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Cord Blood Stem Cell Transplantation*
HLA Antigens*
Peripheral Blood Stem Cell Transplantation*
Transplantation Conditioning*
Busulfan/*administration & dosage
Hematologic Neoplasms/*therapy
Thiotepa/*administration & dosage
Vidarabine/*analogs & derivatives
Adult ; Aged ; Allografts ; Female ; Hematologic Neoplasms/epidemiology ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Vidarabine/administration & dosage
Czasopismo naukowe
Tytuł :
Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML.
Autorzy :
Holtick U; BMT Program, Department I of Internal Medicine, University of Cologne, Kerpener Straße 62, 50924, Köln, Germany. .
Herling M; BMT Program, Department I of Internal Medicine, University of Cologne, Kerpener Straße 62, 50924, Köln, Germany.
Pflug N; BMT Program, Department I of Internal Medicine, University of Cologne, Kerpener Straße 62, 50924, Köln, Germany.
Chakupurakal G; BMT Program, Department I of Internal Medicine, University of Cologne, Kerpener Straße 62, 50924, Köln, Germany.
Leitzke S; BMT Program, Department I of Internal Medicine, University of Cologne, Kerpener Straße 62, 50924, Köln, Germany.
Wolf D; Department III of Internal Medicine, University of Bonn, Bonn, Germany.
Hallek M; BMT Program, Department I of Internal Medicine, University of Cologne, Kerpener Straße 62, 50924, Köln, Germany.
Scheid C; BMT Program, Department I of Internal Medicine, University of Cologne, Kerpener Straße 62, 50924, Köln, Germany.
Chemnitz JM; BMT Program, Department I of Internal Medicine, University of Cologne, Kerpener Straße 62, 50924, Köln, Germany.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2017 Mar; Vol. 96 (3), pp. 479-487. Date of Electronic Publication: 2016 Dec 01.
Typ publikacji :
Journal Article
MeSH Terms :
Whole-Body Irradiation*/mortality
Antineoplastic Agents, Alkylating/*administration & dosage
Busulfan/*analogs & derivatives
Hematopoietic Stem Cell Transplantation/*methods
Leukemia, Myeloid, Acute/*therapy
Transplantation Conditioning/*methods
Adult ; Aged ; Busulfan/administration & dosage ; Female ; Follow-Up Studies ; Hematopoietic Stem Cell Transplantation/mortality ; Humans ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/mortality ; Male ; Retrospective Studies ; Risk Factors ; Survival Rate/trends ; Transplantation Conditioning/mortality ; Transplantation, Homologous/methods ; Transplantation, Homologous/mortality ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).
Autorzy :
Cornillon J; Department of Clinical Hematology, Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France. .
Daguenet E; Department of Clinical Hematology, Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France.
Bay JO; Centre Hospitalo-Universitaire Clermont-Ferrand, Clermont-Ferrand, France.
Chauchet A; Centre Hospitalier Régional Universitaire Besançon, Inserm UMR 1098, Besançon, France.
Salles G; Centre Hospitalier Lyon Sud, Lyon, France.
Contentin N; Centre Henri Becquerel, Rouen, France.
Nicolas-Virelizier E; Centre Léon Bérard, Lyon, France.
Mercier M; Centre Hospitalo-Universitaire d'Angers, Angers, France.
Vallet N; Centre Hospitalo-Universitaire Tours, Tours, France.
Alexis M; Centre Hospitalier Régional Orléans, Orléans, France.
Chrétien ML; Centre Hospitalo-Universitaire Dijon, Dijon, France.
Cluzeau T; Centre Hospitalo-Universitaire Nice, Nice, France.
Huynh A; Centre Hospitalo-Universitaire Toulouse, Toulouse, France.
Himberlin C; Centre Hospitalo-Universitaire Reims, Reims, France.
Dorvaux V; Centre Hospitalier Régional Metz, Metz, France.
Amorim S; Département d'Onco-Hématologie adulte, Hôpital Saint-Louis AP-HP, Paris, France.
Lejeune C; Department of Clinical Hematology, Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France.
de Latour RP; Département d'Hématologie Greffe, Hôpital Saint-Louis AP-HP, Paris, France.
Gyan E; Centre Hospitalo-Universitaire Tours, Tours, France.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2019 Aug; Vol. 98 (8), pp. 1973-1980. Date of Electronic Publication: 2019 May 20.
Typ publikacji :
Journal Article
MeSH Terms :
Bone Marrow Transplantation*
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Lymphoma/*diagnosis
Lymphoma/*therapy
Mucositis/*diagnosis
Transplantation Conditioning/*methods
Adult ; Age Factors ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Busulfan/administration & dosage ; Busulfan/adverse effects ; Cytarabine/administration & dosage ; Cytarabine/adverse effects ; Female ; France ; Humans ; Lymphoma/classification ; Lymphoma/mortality ; Male ; Melphalan/administration & dosage ; Melphalan/adverse effects ; Middle Aged ; Mucositis/chemically induced ; Mucositis/pathology ; Multivariate Analysis ; Prognosis ; Retrospective Studies ; Risk Factors ; Survival Analysis ; Transplantation, Autologous
Czasopismo naukowe
Tytuł :
Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma.
Autorzy :
Hyung J; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Hong JY; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Yoon DH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Kim S; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Park JS; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Park CS; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Lee SW; Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Kim JH; Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Ryu JS; Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Huh J; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Suh C; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2019 Jul; Vol. 98 (7), pp. 1657-1664. Date of Electronic Publication: 2019 Apr 15.
Typ publikacji :
Journal Article
MeSH Terms :
Central Nervous System Neoplasms*/mortality
Central Nervous System Neoplasms*/therapy
Induction Chemotherapy*
Lymphoma*/mortality
Lymphoma*/therapy
Registries*
Stem Cell Transplantation*
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Aged ; Autografts ; Busulfan/administration & dosage ; Consolidation Chemotherapy ; Cyclophosphamide/administration & dosage ; Disease-Free Survival ; Etoposide/administration & dosage ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Prospective Studies ; Survival Rate ; Thiotepa/administration & dosage
Czasopismo naukowe
Tytuł :
Modified BuCy is an alternative conditioning regimen for lymphoma patients undergoing autologous stem cell transplantation.
Autorzy :
Huang H; Department of Hematology, The First Affiliated Hospital of Soochow University, No. 188. Shi Zi Street, Suzhou, 215006, China. .; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, China. .
Zhang L; Department of Hematology, The First Affiliated Hospital of Soochow University, No. 188. Shi Zi Street, Suzhou, 215006, China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, China.
Jiang Y; Department of Hematology, The First Affiliated Hospital of Soochow University, No. 188. Shi Zi Street, Suzhou, 215006, China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, China.
Liu S; Department of Hematology, The First Affiliated Hospital of Soochow University, No. 188. Shi Zi Street, Suzhou, 215006, China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, China.
Jin Z; Department of Hematology, The First Affiliated Hospital of Soochow University, No. 188. Shi Zi Street, Suzhou, 215006, China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, China.
Chen J; Department of Hematology, The First Affiliated Hospital of Soochow University, No. 188. Shi Zi Street, Suzhou, 215006, China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, China.
Xiao X; Department of Hematology, The First Affiliated Hospital of Soochow University, No. 188. Shi Zi Street, Suzhou, 215006, China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, China.
Ruan J; Department of Hematology, The First Affiliated Hospital of Soochow University, No. 188. Shi Zi Street, Suzhou, 215006, China. .; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, China. .; Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York-Presbyterian Hospital, 1305 York Ave., 7th Fl, New York, NY, USA. .
Zhang X; Department of Hematology, The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, No. 1017 Dongmen North Road, Shenzhen, 518020, Guangdong, China. .
Wu D; Department of Hematology, The First Affiliated Hospital of Soochow University, No. 188. Shi Zi Street, Suzhou, 215006, China. .; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, China. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2019 May; Vol. 98 (5), pp. 1259-1266. Date of Electronic Publication: 2019 Jan 12.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Transplantation Conditioning*
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Lymphoma/*mortality
Lymphoma/*therapy
Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Autografts ; Busulfan/administration & dosage ; Busulfan/adverse effects ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Cytarabine/administration & dosage ; Cytarabine/adverse effects ; Disease-Free Survival ; Etoposide/administration & dosage ; Etoposide/adverse effects ; Female ; Humans ; Male ; Melphalan/administration & dosage ; Melphalan/adverse effects ; Middle Aged ; Semustine/administration & dosage ; Semustine/adverse effects ; Survival Rate
SCR Protocol :
BUCY-2 protocol
Czasopismo naukowe
Tytuł :
The incidence and risk factors of hepatic veno-occlusive disease after hematopoietic stem cell transplantation in Taiwan.
Autorzy :
Lee CC; Department of Emergency Medicine, National Taiwan University Hospital, National Taiwan University, College of Medicine, Taipei, Taiwan.
Chang HH; Department of Pediatrics, National Taiwan University Hospital, National Taiwan University, College of Medicine, No. 8 Chung-Shan South Road, Taipei, 10041, Taiwan. .
Lu MY; Department of Pediatrics, National Taiwan University Hospital, National Taiwan University, College of Medicine, No. 8 Chung-Shan South Road, Taipei, 10041, Taiwan.
Yang YL; Department of Pediatrics, National Taiwan University Hospital, National Taiwan University, College of Medicine, No. 8 Chung-Shan South Road, Taipei, 10041, Taiwan.; Department of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University, College of Medicine, Taipei, Taiwan.
Chou SW; Department of Pediatrics, National Taiwan University Hospital, National Taiwan University, College of Medicine, No. 8 Chung-Shan South Road, Taipei, 10041, Taiwan.
Lin DT; Department of Pediatrics, National Taiwan University Hospital, National Taiwan University, College of Medicine, No. 8 Chung-Shan South Road, Taipei, 10041, Taiwan.; Department of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University, College of Medicine, Taipei, Taiwan.
Jou ST; Department of Pediatrics, National Taiwan University Hospital, National Taiwan University, College of Medicine, No. 8 Chung-Shan South Road, Taipei, 10041, Taiwan.
Yao M; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University, College of Medicine, Taipei, Taiwan.
Li CC; Tai-Cheng Stem Cell Therapy Center, National Taiwan University Hospital, Taipei, Taiwan.; Department of Hematology and Oncology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan.
Yeh SP; Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
Chen MH; Department of Nursing, Taichung Veterans General Hospital, Taichung, Taiwan.
Gau JP; Division of Hematology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Li SS; Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
Wang PN; Division of Hematology and Oncology, Department of Internal Medicine, Chang Gung Medical Foundation, Linkou Branch, Taoyuan, Taiwan.
Liu YC; Division of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Wang TF; Department of Hematology and Oncology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan.
Tan TD; Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan.
Lee MY; Division of Hematology and Oncology, Department of Internal Medicine, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan.
Yu MS; Division of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Wang CC; Division of Medical Oncology in the Hematology-Oncology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan.
Lin SC; Division of Medical Oncology and Hematology, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
Chen YC; Division of Hematology and Oncology, Department of Medicine, Tri-Service General Hospital, Taipei, Taiwan.
Su YC; Division of Hematology and Oncology, Department of Medicine, Taipei Medical University-Shuang Ho Hospital, New Taipei City, Taiwan.
Su KY; Department of Emergency Medicine, National Taiwan University Hospital, National Taiwan University, College of Medicine, Taipei, Taiwan.
Lin KH; Department of Pediatrics, National Taiwan University Hospital, National Taiwan University, College of Medicine, No. 8 Chung-Shan South Road, Taipei, 10041, Taiwan.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2019 Mar; Vol. 98 (3), pp. 745-752. Date of Electronic Publication: 2019 Jan 21.
Typ publikacji :
Clinical Trial; Journal Article; Multicenter Study
MeSH Terms :
Registries*
Hematopoietic Stem Cell Transplantation/*adverse effects
Hepatic Veno-Occlusive Disease/*etiology
Hepatic Veno-Occlusive Disease/*mortality
Adolescent ; Adult ; Allografts ; Antilymphocyte Serum/administration & dosage ; Antilymphocyte Serum/adverse effects ; Busulfan/administration & dosage ; Busulfan/adverse effects ; Disease-Free Survival ; Female ; Humans ; Incidence ; Male ; Middle Aged ; Myelodysplastic Syndromes/mortality ; Myelodysplastic Syndromes/therapy ; Risk Factors ; Survival Rate ; Taiwan/epidemiology
Czasopismo naukowe
Tytuł :
Sequential treatment combining cladribine-based re-induction, myeloablative allogeneic HSCT, and prophylactic donor lymphocyte infusion: a promising treatment for refractory acute myeloid leukemia.
Autorzy :
Xiao H; Department of Hematology, Guangzhou General Hospital of Guangzhou Military Command, No. 111 Liuhua Rd., Guangzhou, 510010, Guangdong Province, People's Republic of China. .; Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, People's Republic of China. .
Li L; Center of Cell-Biological Therapy and Research, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, Guangdong Province, People's Republic of China.
Pang Y; Department of Hematology, Guangzhou General Hospital of Guangzhou Military Command, No. 111 Liuhua Rd., Guangzhou, 510010, Guangdong Province, People's Republic of China.
Wu Y; Department of Hematology, Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, People's Republic of China.
Jiang Z; Department of Hematology, Guangzhou General Hospital of Guangzhou Military Command, No. 111 Liuhua Rd., Guangzhou, 510010, Guangdong Province, People's Republic of China.
Liu Z; Department of Hematology, Guangzhou General Hospital of Guangzhou Military Command, No. 111 Liuhua Rd., Guangzhou, 510010, Guangdong Province, People's Republic of China.
Wu J; Center of Cell-Biological Therapy and Research, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, Guangdong Province, People's Republic of China.
Xiao Y; Department of Hematology, Guangzhou General Hospital of Guangzhou Military Command, No. 111 Liuhua Rd., Guangzhou, 510010, Guangdong Province, People's Republic of China.
Huang F; Department of Hematology, Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong Province, People's Republic of China.
Liu Q; Department of Hematology, Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong Province, People's Republic of China.
Zhang H; Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, People's Republic of China.
Luo Y; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, People's Republic of China.
Huang H; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, People's Republic of China.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2018 Dec; Vol. 97 (12), pp. 2479-2490. Date of Electronic Publication: 2018 Aug 04.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Lymphocyte Transfusion*
Tissue Donors*
Cladribine/*administration & dosage
Leukemia, Myeloid, Acute/*mortality
Leukemia, Myeloid, Acute/*therapy
Acute Disease ; Adolescent ; Adult ; Allografts ; Busulfan/administration & dosage ; Child ; Cyclophosphamide/administration & dosage ; Disease-Free Survival ; Female ; Graft vs Host Disease/blood ; Graft vs Host Disease/mortality ; Graft vs Host Disease/prevention & control ; Humans ; Leukemia, Myeloid, Acute/blood ; Male ; Middle Aged ; Prospective Studies ; Survival Rate
Czasopismo naukowe
Tytuł :
Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study.
Autorzy :
Sakellari I; Hematology Department - BMT Unit, G. Papanicolaou Hospital, Exokhi, 57010, Thessaloniki, Greece.
Gavriilaki E; Hematology Department - BMT Unit, G. Papanicolaou Hospital, Exokhi, 57010, Thessaloniki, Greece. .
Chatziioannou K; Department of Radiotherapy, Papageorgiou General Hospital, Thessaloniki, Greece.
Papathanasiou M; Hematology Department - BMT Unit, G. Papanicolaou Hospital, Exokhi, 57010, Thessaloniki, Greece.
Mallouri D; Hematology Department - BMT Unit, G. Papanicolaou Hospital, Exokhi, 57010, Thessaloniki, Greece.
Batsis I; Hematology Department - BMT Unit, G. Papanicolaou Hospital, Exokhi, 57010, Thessaloniki, Greece.
Bousiou Z; Hematology Department - BMT Unit, G. Papanicolaou Hospital, Exokhi, 57010, Thessaloniki, Greece.
Bouziana S; Hematology Department - BMT Unit, G. Papanicolaou Hospital, Exokhi, 57010, Thessaloniki, Greece.
Constantinou V; Hematology Department - BMT Unit, G. Papanicolaou Hospital, Exokhi, 57010, Thessaloniki, Greece.
Douka V; Hematology Department - BMT Unit, G. Papanicolaou Hospital, Exokhi, 57010, Thessaloniki, Greece.
Apostolou C; Hematology Department - BMT Unit, G. Papanicolaou Hospital, Exokhi, 57010, Thessaloniki, Greece.
Iskas M; Hematology Department - BMT Unit, G. Papanicolaou Hospital, Exokhi, 57010, Thessaloniki, Greece.
Lalayanni C; Hematology Department - BMT Unit, G. Papanicolaou Hospital, Exokhi, 57010, Thessaloniki, Greece.
Athanasiadou A; Hematology Department - BMT Unit, G. Papanicolaou Hospital, Exokhi, 57010, Thessaloniki, Greece.
Sotiropoulos D; Hematology Department - BMT Unit, G. Papanicolaou Hospital, Exokhi, 57010, Thessaloniki, Greece.
Yannaki E; Hematology Department - BMT Unit, G. Papanicolaou Hospital, Exokhi, 57010, Thessaloniki, Greece.
Gianouzakos V; Hematology Department - BMT Unit, G. Papanicolaou Hospital, Exokhi, 57010, Thessaloniki, Greece.
Anagnostopoulos A; Hematology Department - BMT Unit, G. Papanicolaou Hospital, Exokhi, 57010, Thessaloniki, Greece.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2018 Oct; Vol. 97 (10), pp. 1987-1994. Date of Electronic Publication: 2018 Jun 05.
Typ publikacji :
Comparative Study; Evaluation Study; Journal Article
MeSH Terms :
Whole-Body Irradiation*
Busulfan/*therapeutic use
Cyclophosphamide/*therapeutic use
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*therapy
Transplantation Conditioning/*methods
Adult ; Age Factors ; Cyclophosphamide/administration & dosage ; Disease-Free Survival ; Female ; Follow-Up Studies ; Graft vs Host Disease/epidemiology ; Graft vs Host Disease/etiology ; Humans ; Infections/epidemiology ; Infections/etiology ; Kaplan-Meier Estimate ; Male ; Remission Induction ; Retrospective Studies ; Risk Factors ; Thrombotic Microangiopathies/epidemiology ; Thrombotic Microangiopathies/etiology ; Transplantation Conditioning/adverse effects ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor.
Autorzy :
Michallet M; Hematology, Blood and Marrow Transplant Unit, Centre Hospitalier Lyon Sud, CHU et Université de Lyon, Lyon, France. />Sobh M
Milpied N
Bay JO
Fürst S
Harousseau JL
Mohty M
Nicolini FE
Labussière H
Tedone N
Morisset S
Vigouroux S
Baumgart J
Tabrizi R
Blaise D
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2012 Aug; Vol. 91 (8), pp. 1289-97. Date of Electronic Publication: 2012 Feb 25.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms :
Histocompatibility*/drug effects
Histocompatibility*/physiology
Unrelated Donors*
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Busulfan/*analogs & derivatives
Hematologic Neoplasms/*therapy
Hematopoietic Stem Cell Transplantation/*methods
Transplantation Conditioning/*methods
Adolescent ; Adult ; Aged ; Antineoplastic Agents, Alkylating/administration & dosage ; Busulfan/administration & dosage ; Dose-Response Relationship, Drug ; Female ; HLA Antigens/immunology ; Hematologic Neoplasms/mortality ; Hematopoietic Stem Cell Transplantation/adverse effects ; Histocompatibility Testing ; Humans ; Male ; Middle Aged ; Prospective Studies ; Transplantation, Homologous ; Young Adult
Czasopismo naukowe
Tytuł :
Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia.
Autorzy :
Chemnitz JM; BMT Program, Department I of Internal Medicine, University of Cologne, Kerpener Straße 62, 50924 Köln, Germany. />von Lilienfeld-Toal M
Holtick U
Theurich S
Shimabukuro-Vornhagen A
Krause A
Brossart P
Hallek M
Scheid C
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2012 Jan; Vol. 91 (1), pp. 47-55. Date of Electronic Publication: 2011 May 17.
Typ publikacji :
Journal Article
MeSH Terms :
Antilymphocyte Serum/*therapeutic use
Antineoplastic Agents, Alkylating/*therapeutic use
Busulfan/*analogs & derivatives
Cyclophosphamide/*therapeutic use
Hematopoietic Stem Cell Transplantation/*methods
Immunosuppressive Agents/*therapeutic use
Leukemia, Myeloid, Acute/*therapy
Transplantation Conditioning/*methods
Adult ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Busulfan/therapeutic use ; Disease-Free Survival ; Female ; Humans ; Leukemia, Myeloid, Acute/prevention & control ; Male ; Middle Aged ; Recurrence ; Transplantation, Homologous/methods ; Whole-Body Irradiation/adverse effects
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies